Breaking news on lupus
Mutation Drives Viral Sensors To Initiate Autoimmune Disease published
Sat, 28 Jan 2012 00:00:00 PST
A new study uses a mouse model of a human autoimmune disease to reveal how abnormal regulation of the intracellular sensors that detect invading viruses can lead to autoimmune pathology...
DNA Sequence Discovered That Causes The Most Severe Cases Of Lupus published
Wed, 18 Jan 2012 00:00:00 PST
A "genetic accelerator" is responsible for the most severe cases of Lupus (systemic lupus erythemathosus), an autoimmune disease: the accelerator, called enhancer HS1.2, speeds up the activity of some critical genes of the immune system involved in the disease. A team of Italian researchers at the Catholic University of Sacred Heart in Rome found that the enhancer HS1...
32 Million Americans Have Autoantibodies That Target Their Own Tissues published
Tue, 17 Jan 2012 00:00:00 PST
More than 32 million people in the United States have autoantibodies, which are proteins made by the immune system that target the body's tissues and define a condition known as autoimmunity, a study shows...
Study: Mycophenolate Is Superior To Azathioprine As Treatment For Lupus Nephritis published
Thu, 17 Nov 2011 03:00:00 PST
A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis...
Hemodialysis Therapy Preferred By Most Lupus Nephritis Patients With End-Stage Renal Disease published
Tue, 08 Nov 2011 03:00:00 PST
Newly published research shows that more patients with end-stage renal disease (ESRD) caused by lupus nephritis choose hemodialysis as their initial kidney replacement therapy over peritoneal dialysis and preemptive kidney transplantation...
Transportation And Childcare Difficulties Top Reasons For Missed Lupus Appointments published
Mon, 07 Nov 2011 01:00:00 PST
The first step towards successful medical care is to see a physician, but for some patients this isn't as simple or easy as it may sound. A study presented at the 2011 Annual Scientific Meeting of the American College of Rheumatology in Chicago, finds that many lupus patients with low socioeconomic status are unable to attend scheduled appointments with physicians due to daily obstacles...
Successful Pregnancy Outcomes For Most Women With Lupus published
Mon, 07 Nov 2011 01:00:00 PST
Promising research led by investigators at Hospital for Special Surgery may offer hope for women with lupus who once thought that pregnancy was too risky. Results from the multicenter National Institutes of Health (NIH) funded PROMISSE initiative, being presented Monday, Nov. 7 and then during a press conference on Tuesday, Nov...
American College Of Rheumatology 2011 Annual Meeting: Presentations By NYU Langone Experts published
Mon, 07 Nov 2011 00:00:00 PST
Experts from NYU Langone Medical Center will present new research findings and clinical insight into the treatment of rheumatic and bone diseases in a variety of presentations at the American College of Rheumatology (ACR) 2011 Annual Scientific Meeting in Chicago, November 5-9, 2011...
XToll Completely Prevented Cutaneous Lupus In Animal Study published
Mon, 31 Oct 2011 09:00:00 PST
CBio Limited have announced the publication of their animal trial on the advanced access site of the Oxford Journals publication, Nephrology Dialysis Transplantation. The research is titled - "Recombinant chaperonin10 (Xtoll) suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice." According to results of the study, using XToll to treat mice completely prevented cutaneous lupus...
Although Atorvastatin Fails To Slow Progression Of Atherosclerosis In Pediatric Lupus Patients, It Is Safe And May Help With More Severe Lupus published
Sun, 30 Oct 2011 00:00:00 PST
Atorvastatin therapy was found to be ineffective in reducing atherosclerosis progression in children and adolescents with systemic lupus erythematosus (SLE)...
A Simpler System Would Make It Easier For Clinicians To Treat Kidney Problems In Lupus Patients published
Sat, 29 Oct 2011 00:00:00 PST
The current classification system for kidney complications in patients with lupus is too detailed, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results should make it easier for physicians to classify and treat kidney problems in patients with the disease...
Statins Disappoint In Atherosclerosis Progression In Children With Lupus published
Fri, 28 Oct 2011 05:00:00 PST
According to the American College of Rheumatology (ACR) 322,000 adult Americans are affected by systemic lupus erythematosus (SLE) with approximately 5,000 to 10,000 children in the U.S. affected by lupus (Lehman 1996), although exact figures for pediatric SLE cases remain difficult to establish...
Continued Treatment For Lupus May Boost Survival Of Those Patients With End-Stage Kidney Disease published
Wed, 21 Sep 2011 02:00:00 PST
Researchers at Albert Einstein College of Medicine of Yeshiva University have shown that close supervision by rheumatologists and the use of immunosuppressant drugs improve the survival of lupus patients with end-stage kidney disease a finding that could reverse long-standing clinical practice. Their study appeared in the September 1 online edition of the Journal of Rheumatology. At least 1...
New Genetic Clue In The Development Of Rheumatoid Arthritis published
Mon, 15 Aug 2011 02:00:00 PST
Scientists at Mount Sinai Hospital, in collaboration with researchers at the University of Toronto, University Health Network and McGill University have obtained significant new insights into the causes of rheumatoid arthritis (RA) and other autoimmune disorders including type 1 diabetes, lupus and Graves disease...
Gender Difference In Autoimmune Disease Explained By Newly Discovered B Cells published
Mon, 08 Aug 2011 00:00:00 PST
Researchers at National Jewish Health have discovered a type of cell that may contribute to autoimmune disease. The findings also suggest why diseases such as lupus, multiple sclerosis and rheumatoid arthritis strike women more frequently than men. The cells, a subset of immune-system B cells, make autoantibodies, which bind to and attack the body's own tissue...
Vitamin D Deficiency Among Systemic Lupus Erythematosis Patients published
Thu, 04 Aug 2011 14:00:00 PST
Researchers have just found that vitamin D levels among systemic lupus erythematosis (SLE) patients directly relates to the severity of the disease and the development of the infection. The study found that people with low levels of vitamin D are more prone to develop SLE than those with higher levels...
Glaxo's Revolutionary Lupus Treatment Benlysta Now EU Approved published
Fri, 15 Jul 2011 11:00:00 PST
The first treatment developed for lupus in over 50 years has finally been approved by the European Union this week. The watchdog, European Medicines Agency, has backed the injectable drug that will cost Europeans $23,000 USD a year. Already approved in the United States in March 2011, the drug costs Americans $35,000 USD annually. Benlysta's annual global sales are expected to reach $3...
Study Of African-American Women Reveals New Genetic Risk Factors Of Lupus published
Sun, 26 Jun 2011 03:00:00 PST
Researchers from Boston University's Slone Epidemiology Center have found four new genetic variants in the major histocompatibility complex (MHC) that confer a higher risk of systemic lupus erythemathosus ("lupus") in African American women...
LFA Represents Lupus Community At Pediatric Rheumatic Drug Treatment Meeting published
Mon, 13 Jun 2011 09:00:00 PST
Today, Sandra C. Raymond, President and CEO of Lupus Foundation of America, will be representing the lupus advocacy community at a meeting of key stakeholders from the federal government, industry, and academia where they will be discussing pediatric rheumatic drug treatments and a consolidated adverse events registry...
Survey Reveals Lupus' Ability To Wreck Careers published
Sun, 29 May 2011 02:00:00 PST
Lupus has a profoundly negative effect on the working lives of sufferers', found a survey of over 2,000 lupus patients presented at the Annual Meeting of the European League Against Rheumatism (EULAR) in London, May 25-28. "We've shown just how debilitating lupus can be in terms of the number of patients having to stop work, change their jobs or apply for sick leave...
EULAR 2011 - Vidofludimus Superior To Cyclophosphamide And MMF In An Experimental Systemic Lupus Erythematosus Model published
Fri, 27 May 2011 09:00:00 PST
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus (SLE) at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, i...
Results Showed 7 Out Of 10 Patients Reported That Lupus Affected Their Careers published
Fri, 27 May 2011 04:00:00 PST
LUPUS EUROPE (LE) and UCB today announced results from the pan-European Lupus European Online (LEO) survey, believed to be the first online survey of its kind completed by lupus patients using validated measures assessing the impact of lupus. These patient-reported outcome (PRO) measures included assessments of fatigue, work impairment and health-related quality of life...
Disease Activity In Systemic Lupus Erythematosus Patients Not Increased By The HPV Vaccine Gardasil published
Fri, 27 May 2011 03:00:00 PST
Results of a Chinese study showed that the HPV vaccine did not have significant effects on the number of disease flares or antibody measures in patients with inactive SLE receiving stable doses of medications after administration, and therefore was determined safe to use to prevent HPV in this group of patients...
GlaxoSmithKline And Human Genome Sciences Receive Positive Opinion In Europe From The CHMP For BenlystaŽ (belimumab) published
Sat, 21 May 2011 00:00:00 PST
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc...
GSK Lupus Treatment Benlysta Reaches Europe After US Approval published
Fri, 20 May 2011 10:00:00 PST
The first treatment developed for lupus in over 50 years has been reocommended for approval by the European Union this week. The watchdog, European Medicines Agency has backed the injectable drug that will cost Europeans $23,000 USD a year. Already approved in the United States in March 2011, the drug costs Americans $35,000 USD annually...
)
|
|
